Henn Matthew R 4
4 · Seres Therapeutics, Inc. · Filed Nov 18, 2025
Insider Transaction Report
Form 4
Henn Matthew R
See Remarks
Transactions
- Sale
Common Stock
2025-11-15$17.30/sh−1,257$21,746→ 7,527 total - Exercise/Conversion
Restricted Stock Units
2025-11-15−140→ 704 total→ Common Stock (140 underlying) - Exercise/Conversion
Common Stock
2025-11-15+3,998→ 8,546 total - Exercise/Conversion
Common Stock
2025-11-15+98→ 8,784 total - Exercise/Conversion
Common Stock
2025-11-15+140→ 8,686 total - Exercise/Conversion
Restricted Stock Units
2025-11-15−98→ 878 total→ Common Stock (98 underlying) - Exercise/Conversion
Restricted Stock Units
2025-11-15−3,998→ 0 total→ Common Stock (3,998 underlying)
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F3]The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date.
- [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- [F5]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.